Narrow Main Beam, Low Side Lobes! High-Performance Electro-Optic Beam Steering with Thin-Film Lithium Niobate Optical ...

Beam Therapeutics BEAM shares are rising Tuesday after the company reported quarterly results. Beam Therapeutics stock is surging to new heights today. What’s fueling BEAM momentum? Beam Surpasses ...

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Analysts have set 12-month price targets for Beam Therapeutics, revealing an average target of $44.5, a high estimate of $74.00, and a low estimate of $28.00. This current average reflects an increase ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, ...

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C.

In recent days, Cathie Wood’s ARK Invest has materially increased its holdings in Beam Therapeutics, adding more than 195,000 shares across its genomics-focused funds as it leans further into ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...